Setrobuvir
From Infogalactic: the planetary knowledge core
200px | |
Names | |
---|---|
IUPAC name
N-(3-{(4aR,5S,8R,8aS)-1-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2,4a,5,6,7,8,8a-octahydro-5,8-methanoquinolin-3-yl}-1,1-dioxo-1,4-dihydro-1λ6,2,4-benzothiadiazin-7-yl)methanesulfonamide
|
|
Other names
ANA-598; ANA598
|
|
Identifiers | |
1214735-09-7 ![]() 1071517-39-9 ![]() |
|
ChEMBL | ChEMBL1076263 ![]() |
ChemSpider | 24680206 ![]() |
Jmol 3D model | Interactive image |
KEGG | D10165 ![]() |
PubChem | 45136829 |
|
|
|
|
Properties | |
C25H25FN4O6S2 | |
Molar mass | 560.62 g·mol−1 |
Vapor pressure | {{{value}}} |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
![]() ![]() ![]() |
|
Infobox references | |
Setrobuvir (INN,[1] USAN,[2] also known as ANA-598) was an experimental drug candidate for the treatment of hepatitis C. It was discovered at Anadys Pharmaceuticals. In 2011, Roche acquired Anadys in order to develop setrobuvir.[3] It was in Phase IIb clinical trials, used in combination with interferon and ribavirin,[4] targeting hepatitis C patients with genotype 1.[3]
Setrobuvir works by inhibiting the hepatitis C enzyme NS5B, an RNA polymerase.[5]
Its development was discontinued on July 15, 2015.[6]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Statement on a Nonproprietary Name Adopted by the USAN Council
- ↑ 3.0 3.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>